Form 4: Vericel Corp Executive Jonathan Hopper Reports Stock Transactions

Chief Medical Officer Jonathan Hopper reports exercising stock options and selling shares of Vericel Corp under a pre-arranged trading plan.

Summary

• Jonathan Hopper, Chief Medical Officer of Vericel Corp, reported transactions involving the company's stock on March 3, 2025.
• Hopper exercised options to acquire 10,000 shares of common stock at a price of $18 per share.
• Simultaneously, Hopper sold 10,000 shares of common stock at a price of $49.53 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on May 28, 2024.
• Following these transactions, Hopper directly owns 66,101 shares of Vericel Corp common stock and holds options to purchase 28,750 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is a standard practice in publicly traded companies.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent routine insider trading activity under a pre-arranged plan.
• Shareholders may view the filing as part of the overall transparency of the company's operations.

Key Dates